WP
ABCL icon

Woodline Partners’s AbCellera Biologics ABCL Stock Holding History

Woodline Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,163
Closed -$36K – 587
2024
Q2 		$36K Buy
+12,163
New +$46K ﹤0.01% 544
2022
Q2 		– Sell
-136,910
Closed -$1.33M – 793
2022
Q1 		$1.33M Sell
136,910
-533,729
-80% -$5.05M 0.02% 447
2021
Q4 		$9.59M Buy
670,639
+273,823
+69% +$4.16M 0.14% 206
2021
Q3 		$7.95M Hold
396,816
– – 0.13% 190
2021
Q2 		$8.73M Buy
396,816
+141,914
+56% +$3.91M 0.16% 148
2021
Q1 		$8.66M Sell
254,902
-176,185
-41% -$7.02M 0.19% 137
2020
Q4 		$17.3M Buy
+431,087
New +$19.7M 0.46% 69

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Woodline Partners's ABCL Position: Q3 2024 in Review

Woodline Partners sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 12,163 shares — an estimated $36K sold.

Woodline Partners first reported a position in ABCL in Q4 2020 and held it in 7 quarters. The position peaked at $17.3M in Q4 2020. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • Woodline Partners reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
  • Woodline Partners sold 12,163 AbCellera Biologics shares in Q3 2024, an estimated $36K.
  • Woodline Partners first reported a position in AbCellera Biologics in Q4 2020 and held it in 7 quarters.
  • Woodline Partners's AbCellera Biologics position peaked at $17.3M in Q4 2020.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.